DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Adults aged ≥18 years [+4]
Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon o... [+3]